Gooch & Housego Posts 91% Profit Surge Amid Strategic Acquisitions

A Stellar Surge: G&H Flexes Its Photonics Muscle

Well, well, well. Gooch & Housego (AIM: GHH) hasn’t just nudged the dial forward; they’ve given it a hefty shove. Their H1 2025 results, hot off the press, reveal a company firing on multiple strategic cylinders. That eye-popping 91% surge in adjusted profit before tax (to £5.1m) isn’t just luck – it’s the sound of a focused strategy hitting paydirt. Buckle up; this is a fascinating tale of resilience, acquisition savvy, and photonics prowess.

The Numbers Don’t Lie: Core Performance Leaps Forward

Let’s cut straight to the juicy bits:

• Revenue Up 11.4%: £70.9m (H1 2024: £63.6m), driven by strong organic growth (7.5% constant currency) and the Phoenix acquisition.
• Adjusted PBT Skyrockets 91%: £5.1m (vs £2.6m). This is the headline grabber for good reason.
• Operating Margins Strengthen: Jumped to 8.7% (from 6.0%) – clear evidence of operational improvements biting.
• Order Book Bulging: Grew significantly to £121.5m (Sept ’24: £104.5m), with Phoenix contributing ~£7m and organic growth robust. Future revenue visibility looks solid.
• A&D Segment Turns Profitable: A major milestone, swinging from a £1.6m loss H1 ’24 to a £0.6m profit. The turnaround strategy is bearing fruit.
• Dividend Steady: Interim dividend maintained at 4.9p per share, though the Board hints at a future policy review to potentially optimise capital allocation.

CEO Charlie Peppiatt nailed it: this performance against a “challenging macroeconomic background” showcases the “positive progress” of their new strategy and the team’s resilience.

Where the Growth Came From: Segment Deep Dive

G&H’s three core segments painted a varied but ultimately positive picture:

Aerospace & Defence (A&D): The Star Performer

• Revenue Boom: Up 41.4% (£23.5m), or a stellar 30% organic. Demand is strong across the board.
• Turnaround Complete: Profit of £0.6m vs last year’s loss. Operational fixes at Moorpark (CA) and increased subsystem content are key drivers.
• Defence Tailwinds: Ukraine conflict and rising NATO budgets are driving enquiries. New periscope system deliveries (e.g., Challenger MBT upgrade) are progressing well.

Life Sciences: Solid Growth, Strategic Shifts

• Revenue Up 12.7% (£17.3m): Driven by medical diagnostics ramp-up. The new Rochester (NY) facility is operational and certified (ISO 13485/FDA).
• Margin Pressure & Pruning: Margins dipped slightly (12.0% vs 14.7%) due to volume price steps and competition. Crucially, G&H is proactively exiting most medical laser Pockels cell lines facing low-cost Chinese competition, focusing Cleveland (OH) on crystal growth instead. Last-time-buy orders will cover ~£4-5m annual revenue for 18 months.

Industrial: A Mixed Bag Amidst Headwinds

• Revenue Dip 4.9% (£30.1m): Subsea data cable growth was strong, but weakness persisted in industrial lasers and semiconductors (customer capex hesitation due to tariffs/uncertainty).
• Margin Silver Lining: Despite lower revenue, adjusted operating profit rose 10.2% (£3.8m), with margins up to 12.6%. Outsourcing lower-margin products and shifting to complex assemblies paid off.

The Acquisitions Engine: Phoenix Integrated, Global Photonics Onboard

G&H’s “speed to value” M&A strategy is central to its growth narrative:

• Phoenix Optical (Acquired Oct ’24): Integration is “proceeding to plan.” Already securing new orders (£7m added to order book) and realising operational synergies (combined capacity planning). Based in St. Asaph, Wales, it bolsters UK/European A&D optics.

• Global Photonics (Agreed May ’25): This US near-Tampa acquisition is strategic gold. It brings:

  • Critical US A&D footprint (periscopes, fire-control systems, air platform instrumentation).
  • Complementary tech (cleanroom lithography, reticle fab, ion beam etching, advanced coatings).
  • Strong relationships with US defence primes.
  • FY24 Revenue: ~$11.1m, Adj. EBITDA ~$1.8m.

  Consideration: $17.5m ($8.75m cash, $8.75m G&H shares). This mirrors the successful UK optical systems hub strategy and builds a US counterpart to the Rochester Life Sciences hub.

The message is clear: G&H is building a formidable, geographically diversified optical systems powerhouse, particularly in the resilient A&D sector.

Strategy Execution: The Four Pillars Bearing Weight

Peppiatt emphasised the new strategy’s role. The progress on the four pillars is tangible:

1. People: New HR systems, revised sales incentives, safety focus (zero RIDDORs), ISO 14001 rollout (5/10 sites now certified).
2. Self-Help (Ops & Customer Exp): Commercial team reorg, improved on-time delivery (especially Moorpark), successful outsourcing ramp-up (fibre couplers), Rochester facility build-out.
3. Technology: Focused R&D spend (£3.5m), key wins in fibre optics (subsea/semiconductor), precision optics (tank sights, DUV coatings), Life Sciences hub launch.
4. Investment: Successful Phoenix integration, active working capital management (though inventory up due to Germanium stockpiling), disciplined capex, portfolio pruning (EM4 divested, Pockels cells exiting), and the Global Photonics deal.

Debt, Cash & The Road Ahead: Confidence Tempered by Caution

• Net Debt: Increased to £35.5m (inc. leases; £24.1m ex-IFRS 16) due to Phoenix acquisition and inventory build (Germanium sourcing).
• Leverage: Comfortable at 1.3x (ex-IFRS 16). Crucially, facilities were extended to March 2030 post-period, with an increased $55m committed facility ($60m post-Global Photonics close) and improved margin grid.
• Outlook: Management’s FY25 expectations are unchanged (>95% order cover). However, they flag “increased execution risks” due to:
  • Global uncertainty & tariff volatility (US & retaliatory measures).
  • Potential supply chain disruption (material sourcing, e.g., Germanium).
  • Customer capex delays (especially Industrial/Life Sciences).
• Long-Term Target: Mid-teens return on sales by 2028 remains the goal.

Peppiatt’s closing remarks sum up the balancing act: “With our growing order book, strengthening market positions and differentiated photonics expertise… we remain confident… though there are increased execution risks.”

The Takeaway: Optics Have Never Looked Sharper

Gooch & Housego’s H1 is undeniably impressive. That 91% profit surge isn’t a fluke; it’s the result of sharp strategic execution – integrating acquisitions (Phoenix, soon Global Photonics), ruthlessly focusing the portfolio (exiting low-margin lines), driving operational efficiencies, and capitalising on structural A&D growth. While tariff wars and global uncertainty inject near-term caution, the order book provides a robust buffer, and the strategic moves position G&H for sustainable, higher-margin growth. The journey to mid-teens returns by 2028 looks firmly on track. For investors seeking exposure to high-tech manufacturing with defence tailwinds and savvy management, G&H is putting on quite the show. Keep your periscopes trained on Ilminster.